JAK inhibitor Rinvoq treatment of specific dermatitis: Phase III clinically showed significant efficacy.

The !---- Avie's Rinvoq monotherapy reached the primary and secondary endpoint in the Measure Up 2 trial, a Phase II Phase III study of patients with moderate to severe allergic dermatitis.main endpoints: the eczema area severity index (EASI 75) is at least 75% higher than the baseline, and the global assessment verifies that the adhesional dermatitis (vIGA-AD) score for the 16th week is 0/1 (clear or almost clear).Rinvoq is an oral, daily, selective and reversible JAK inhibitor approved in Europe for the treatment of patients with moderate to severe active rheumatoid arthritis who respond poorly or intolerance to one or more disease-relieving anti-rheumatoids.Photo Source: At the 16th week, patients treated with 15 mg/30 mg of Rinvoq in two doses compared to placebo, had a significant increase in skin removal rate and itchreduction reduction, with 60% and 73% of patients reaching EASI 75, respectively, compared to 13% of the placebo group.IGA-AD 0/1 was 39% and 52%, respectively, and 5% in the placebo group. Michael Severino, Vice Chairman and President of abbVie,, said: "We are encouraged by these results, which re-validated The Data for Measure Up 1 and highlight the potential therapeutic value of Rinvoq for patients with teriotitis." at week 16, patients treated with 15 mg/30 mg doses of Rinvoq showed clinical lysination, compared with 9% of patients receiving a placebo.AbbVie also stressed that no new safety risks were found compared to patients with rheumatoid arthritis and psoriasis treated with Rinvoq..